Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley as a new board member, starting May 15, 2022.
Hedley will serve on the board committees related to science and technology, and ethics and compliance.
Hedley is an immunologist and cancer cell biologist with substantial experience in the pharma industry.
Hedley has worked as a senior scientific fellow at the Broad Institute of MIT and Harvard and has served as director, president and chief operating officer of Tesaro, an oncology-focused biotech company she co-founded in 2010. Tesaro commercialized Zejula (niraparib), a PARP inhibitor used for ovarian cancer, fallopian tube and primary peritoneal cancer. GSK acquired Tesaro in 2019 for more than $5 billion.
In 2017, Hedley was awarded an EY Entrepreneurs of the Year Overall National Award.
Hedley has also held senior roles at the biotech Abraxis BioSci…